MedPath

Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp

Phase 4
Completed
Conditions
Gastric Polyp
Helicobacter Pylori Infection
Interventions
Drug: H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
Registration Number
NCT03065868
Lead Sponsor
Kyungpook National University Hospital
Brief Summary

Evaluation of the effect of H. pylori eradication on regression of H. pylori-related gastric polyp (Ranomized controlled trial)

1. Study design: open labeled RCT

2. Study group H. pylori eradication group (N=17), non-eradication group (N=15)

3. Treatment plan

1. Baseline EGD

: 0.3-1cm sized polyp - bx \& CLO test (antrum \& body)

==\> if H. pylori positive and eligible patients, randomization

2. Triple therapy

3. UBT (4week after eradication)

4. Follow-up EGD: gross finding, CLO test

4. Evaluation of polyp regression

1. disappear

2. regression over 50% (size, number)

3. no change or increase (size, number)

Detailed Description

(A) Study population

1. inclusion HP-realetd polyp polyp size with 0.3cm-1cm 20 yr - 70yr

2. exclusion peptic ulcer, healing stage or acute stage recent use of PPI within 4weeks Liver cirrhosis, renal insufficiency, other serious chronic or acute disease current infection of other bacteria, virus, or fungus cancer, psychologic disease heavy drinker drug abuser pregnant women, Penicillin allergy, digoxin, antifungal, wafarin previosu H. pylori eradication enroll gastric polyp with bleeding or malignant transformation tiny polyp less than 3mm.

(B) Study method

1. Study design: open labeled RCT

2. Study group H. pylori eradication group (N=17), non-eradication group (N=15)

3. Treatment plan

1. Baseline EGD: 0.3-1cm sized polyp - bx \& CLO test (antrum \& body) ==\> if H. pylori positive and eligible patients, randomization

2. Triple therapy

3. UBT (4week after eradication) if eradication failure in triple therapy, 2nd line treatment (metroniazole based quadraple therpay) and the UBT (4week after eradication)

4. Follow-up EGD (3-9M): gross finding, CLO test

4. Evaluation of polyp regression

1. disappear

2. regression over 50% (size, number)

3. no change or increase (size, number)

5. Statistical analysis

1. Chi-square test to compare polyp regression between treatment \& control group.

2. t-test to compare continuous variables between treatment \& control group.

3. Paired T-test to compare the size between baseline and follow-up EGD.

4. Regression analysis: univariate \& multivariate analysis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
32
Inclusion Criteria
  • Gastric polyp with current infection of H. pylori
  • Gastric polyp size with 3mm-10mm
  • Age of 20 yr - 70yr
Exclusion Criteria
  • Gastric ulcer ir duodenal ulcer (healing stage or acute stage)
  • Use of PPI within 4weeks
  • Liver cirrhosis, renal insufficiency, other serious chronic or acute disease
  • Current infection of other bacteria, virus, or fungus
  • Any cancer, psychologic disease
  • Heavy drinker
  • Drug abuser
  • Pregnant women
  • Penicillin allergy
  • Use of digoxin, antifungal, wafarin
  • Previous H. pylori eradication
  • Gastric polyp with bleeding or malignant transformation
  • Tiny polyp less than 3mm.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
eradictaionH. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)H. pylori eradication group
Primary Outcome Measures
NameTimeMethod
Compare regression rate of gastric polyps between H. pylori eradication and non-eradication groups. Regression of gastric polyp: one of below 1) Disappearance of gastric polyp 2) Reduction of polyp size over 50%up to 24months

Evaluation of the effect of H. pylori eradication on the regression of H. pylori associated gastric polyp

Study group

1. H. pylori eradication

2. H. pylori non-eradication

Definition of gastric polyp change:

1. Disappearance of gastric polyp

2. Reduction of polyp size over 50%

3. No change of size or increased size

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Su Youn Nam

🇰🇷

Daegu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath